CICC Fund led Haina Pharmaceutical 100 million yuan in financing

"Science and Technology Board Daily" on the 16th, Nanjing Hainan Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Haina Pharmaceutical") completed a new round of equity financing in August 2022. This financing was based on CICC Capital Capital Capital Investment in the funds of the funds, Shanlan Capital, Jiangxi State Control Industry Development Fund, etc. Investment, all of which will be used for the layout of R & D pipelines and the expansion of the R & D team.

According to the company's information, Hainan Pharmaceutical was established in 2001. It is a professional service for partners to provide new drug discovery, pharmaceutical research, clinical research, biological sample testing, drug registration, and drug production. CDMO services are high -tech enterprises with characteristics. At present, the company owns two R & D centers in Gulou District, Nanjing City and Jiangbei New District. It has a R & D area exceeding 5,000 square meters and a total investment of more than 400 million yuan. It has a complete pharmaceutical research and development equipment and management system. It is reported that Haina Pharmaceutical has obtained a series of honors and qualifications such as high -tech enterprises, Jiangsu Engineering Technology Center, Jiangsu Graduate Workstation, 2017 China Pharmaceutical R & D brand, and 2020 Chinese CDMO companies.

Product services provided by Heine Pharmaceuticals include CDMO, consistency evaluation, approval transfer, technical development, clinical and testing. At present, Haina Pharmaceutical has more than 20 products for listing, more than 60 reviews or research projects, and provides more than 500 professional services such as CRO and CDMO for more than 100 domestic cooperative customers. The company's product declaration quantity and review pass rate ranks among the forefront of the country in the same industry, and the retirement rate due to technical reasons is zero. In addition, on its own product line, the company has more than 10 production workshops such as oral solid -solid preparations, oral liquid systems, injections, microne pills, gel agents, gel agents, and plaster paste. In the future, Haina Pharmaceutical will be committed to leading domestic drug research and development towards more professional and more efficient directions.

According to smart bud data, Haina Pharmaceutical and its related companies currently have more than 100 patent applications, of which more than 90 invention patents are invention. The company's patent layout is mainly focused on the relevant areas such as testing methods, flow phases, and active components.

- END -